• JUser: :_load: Unable to load user with ID: 44
Category: Manufacturing

Hyderabad, April 10, 2014 - 
Neuland Laboratories rose 2.34% to Rs 260 at 14:24 IST on BSE after the company said it has opened a new manufacturing facility in Hyderabad, constructed as part of its collaboration with Tokyo-based API Corporation.

The announcement was made on Tuesday, 8 April 2014. The stock market was closed on that day, on account of Ram Navami.

Meanwhile, the S&P BSE Sensex was up 210.32 points or 0.94% at 22,553.77.

On BSE, so far 1,007 shares were traded in the counter as against average daily volume of 14,578 shares in the past one quarter.

The stock hit a high of Rs 265 and a low of Rs 255.15 so far during the day. The stock had hit a record high of Rs 370.40 on 19 December 2013. The stock had hit a 52-week low of Rs 88.50 on 13 June 2013.

The stock had underperformed the market over the past one month till 7 April 2014, declining 4.06% compared with the Sensex's 1.93% rise. The scrip had also underperformed the market in past one quarter, sliding 24.82% as against Sensex's 7.97% rise.

The small-cap company has equity capital is Rs 7.66 crore. Face value per share is Rs 10.

Neuland Laboratories said that the new manufacturing facility, which is located in a Neuland complex in Pashamylaram, Hyderabad, is the first manufacturing facility that API Corporation (APIC) has established outside of Japan.

Pursuant to an agreement entered into in March, 2013, Neuland constructed and will operate these manufacturing facilities dedicated to providing APIC with capacity for meeting the needs of its customers for pharmaceutical APIs and intermediates.

Kiyoshi Kondo, President and CEO of APIC said, "We welcome the inauguration of our dedicated Neuland manufacturing facility, a world-class operation that has come online just a year after our collaboration agreement was signed. This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland, a company with a long history of outstanding quality and regulatory excellence".

"We are pleased to inaugurate these new state-of-the-art manufacturing facilities developed as part of our collaboration with APIC", said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. "This arrangement allows APIC to expand their business in Japan in a timely and cost-effective way, while also helping to raise Neuland's profile as a quality supplier of APIs and intermediates to the Japanese market", M. Rao added.

Tokyo-based API Corporation (APIC) is healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs, along with fine chemicals and reagents.

Neuland Laboratories' net profit surged 108.6% to Rs 6.82 crore on 22.8% growth in net sales to Rs 130.83 crore in Q3 December 2013 over Q3 December 2012.

For 30 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in 85 countries.

Category: Manufacturing
Company losing production on around 150 machines per day

Ahmedabad  February 1st, 2014: As the tussle between a set of workers and management continues at 
's  in the outskirts of Ahmedabad, the facility is incurring a daily loss in production of around 150,000-190,000 tablets and capsules per machine.

Around 350 workers have not reported to work at the Moraiya plant since Thursday, demanding a re-instatement of terminated workers.

With two workers operating a machine, nearly 150 machines are not productive at the plant.

A worker at the plant informed on grounds of anonymity that a machine can churn out around 400 tablets/capsules per minute, and they work an eight-hour shift.

It is difficult to gauge the production loss in terms of value, but in terms of volume, around 150,000-190,000 tablets/capsule production is likely to be affected.

Analysts said that it is difficult to calculate the production loss in value terms, as different medicines are priced differently.

However, they estimate the production from Moraiya, which is a US Food and Drug Administration () approved plant, to be in the range of $35-45 million during the 2013-14 fiscal.

"Zydus had exported around $275 million to the US market in FY13, and by the end of this fiscal it is expected to export around $310-320 million worth of drugs. The incremental revenues would come from the new approvals which are getting produced at Moraiya," explained a Mumbai based analyst.

Prafful Bohra of  said that the Moraiya facility had received a warning letter from the USFDA which was revoked around July 2012. "After that, Zydus has received some product approvals in the US, not many, which are made at Moraiya.

The company is expected to resolve the labour issue soon and hence a significant impact on production is not expected," he said.

The company did not wish to comment on the matter.

The Moraiya facility has over 2,000 workers.

A worker at the plant claimed that with 350 operators not reporting to work, per machine at least 10 more people downstream (who pack medicines, among other things) are left with no work at the plant.

Earlier this week, around 350-360 workers had protested outside the factory gates and stayed away from work.

They were demanding a roll-back of the newly implemented system of commissioning one worker per machine instead of the earlier system of two workers per machine.

Most workers had joined work on Wednesday.

However, following the arrest of two workers and a termination of around 60 workers, around 350 workers decided to stay away from work from Thursday.

The company too had posted a notice outside the factory gates terming the workers' action as an illegal strike.

Workers, senior human resources managers held a meeting today afternoon, however, no resolution has been reached.

A worker present at the meeting informed, "The meeting went well, and in an amicable environment. The company is yet to take a decision on taking back the terminated workers, and a follow-up meeting has been scheduled for next Wednesday. We are hopeful that the issue would be solved soon."

The worker added that workers would not report to work until the sacked employees are re-instated.-Business Standard 
Category: Manufacturing

Bangalore January 04, 2014:
Elder Pharmaceuticals Ltd (EPL), a drug firm plans to expand its horizons by focusing on brand building and plans to enter into newer therapeutic areas. The firm has plans to build and focus on their domestic market of anti-infectives and also expand its business in Europe and in the UK. The drug company also aims to strengthen its in-licence portfolio.

Along with these expansion plans, Elder pharma also prepares to explore the possibility of venturing into new therapeutic areas. As the firm expects an increase in its revenues, it aims at restructuring and restrategising its brands. While the company has already been seeing profits with its division of anti-infectives, the additional areas can prove to be more beneficial.

Now, Elder pharma aims at focusing on increasing its presence in the areas of injectables and anti-infectives to continue with the company’s growth. The company would additionally focus on creating a brand leadership in a particular segment by creating a product in a therapeutic category and develop its own portfolio. The other therapeutic areas that the company aims to concentrate on include neurological and cardio-vascular segments. -IGMPI

Email address:

Prev Next
"ACCURA" MODEL ACT -III High Speed Double Rotary Tablet Presses
Pharmaceutical Labeling Equipment
The Power Times.in
The SME Times
 The Pharma Times News Portal
The Hotel Times
  • 1
  • 2
Prev Next
Omron Blood Pressure Monitor, HEM-7113
Automatic Capsule Filling Machine (PF-150)
Gelusil liquid antacid - Pfizer’s
The Varilux 3.0 range lenses - Essilor
Blossom Kochhar Aroma Magic Anti Pigmentation Serum
 The Property Times